MARKET

VERU

VERU

Veru
NASDAQ
0.7399
+0.0933
+14.43%
Opening 15:43 03/28 EDT
OPEN
0.6900
PREV CLOSE
0.6466
HIGH
0.7697
LOW
0.6900
VOLUME
5.63M
TURNOVER
0
52 WEEK HIGH
1.520
52 WEEK LOW
0.3600
MARKET CAP
108.31M
P/E (TTM)
-0.6754
1D
5D
1M
3M
1Y
5Y
Veru Price Target Announced at $3.00/Share by Raymond James
Dow Jones · 22h ago
Veru Initiated at Outperform by Raymond James
Dow Jones · 22h ago
Raymond James Initiates Coverage On Veru with Outperform Rating, Announces Price Target of $3
Benzinga · 22h ago
Weekly Report: what happened at VERU last week (0318-0322)?
Weekly Report · 3d ago
Veru Reschedules Annual Meeting of Shareholders
Barchart · 6d ago
Weekly Report: what happened at VERU last week (0311-0315)?
Weekly Report · 03/18 11:29
Press Release: Veru Announces the Appointment of Louis Aronne MD as Chief Medical Advisor for its Enobosarm Program for High Quality Weight Loss
Veru Announces the Appointment of Louis Aronne MD as Chief Medical Advisor for its Enobosarm Program for High Quality Weight Loss. Dr. Aronne is a leading authority on obesity and its treatment. Veru is developing a drug to avoid muscle loss and augment fat loss when combined with a GLP-1 drug.
Dow Jones · 03/12 12:00
Press Release: Veru Announces the Appointment of -2-
This press release contains "forward-looking statements" Veru Inc. Is a late-stage biopharmaceutical company focused on obesity and oncology. The Company's actual results could differ from those expressed or implied by such statements. The company's planned phase 2b trial of enobosarm is under way.
Dow Jones · 03/12 12:00
More
About VERU
Veru Inc. is a biopharmaceutical company. The Company is focused on developing medicines for the for the treatment of hospitalized COVID-19 patients at high risk for acute respiratory distress syndrome (ARDS) and other viral-related ARDS and for the management of breast and prostate cancers. The Company offers two FDA approved products within its sexual health program, including ENTADFI (tadalafil 5mg and finasteride 5mg capsule), for the treatment of benign prostatic hyperplasia and FC2 Female Condom (internal condom) (FC2), for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. Its breast cancer drug pipeline has four clinical development programs for two drugs, such as enobosarm, an oral selective androgen receptor targeting agonist, and sabizabulin, an oral cytoskeleton disruptor. Its prostate cancer drug pipeline includes sabizabulin, VERU-100 and zuclomiphene citrate.

Webull offers Veru Inc stock information, including NASDAQ: VERU real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VERU stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading VERU stock methods without spending real money on the virtual paper trading platform.